Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Gilles Salles(Memorial Sloan Kettering Cancer Center), Andrew Spencer(The Alfred Hospital), John Radford(Manchester Academic Health Science Centre), Georg Heß(Johannes Gutenberg University Mainz), Peter Martin(Northwestern University), Nathan Fowler(Repligen (United States)), Michael Schäffer(UPMC Hillman Cancer Center), Jessica Vermeulen(UPMC Hillman Cancer Center), Rajendra N. Damle(UPMC Hillman Cancer Center), Abdulraheem Yacoub(The University of Kansas Cancer Center), Sriram Balasubramanian(Pharmacyclics (United States)), Shean‐Sheng Wang(UPMC Hillman Cancer Center), Sanjay Deshpande(Janssen (United States)), Stephen J. Schuster(Hospital of the University of Pennsylvania), Gary Gartenberg(UPMC Hillman Cancer Center), Bruce D. Cheson(Center for Cancer and Blood Disorders), Judith Trotman(The University of Sydney), Wojciech Jurczak(Jagiellonian University), Jing-Zhou Hou(University of Pittsburgh Medical Center), James Morton(UPMC Hillman Cancer Center), Umberto Vitolo(Candiolo Cancer Institute), Dolores Caballero(Complejo Hospitalario de Salamanca), Michael Lill(Cedars-Sinai Medical Center)
Cited by 103
Related Papers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k